{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:14:16Z","timestamp":1740158056217,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T00:00:00Z","timestamp":1613865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T00:00:00Z","timestamp":1613865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01HG010232"],"award-info":[{"award-number":["U01HG010232"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl. Stroke Res."],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12975-021-00896-3","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T08:02:47Z","timestamp":1613894567000},"page":"46-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5398-2085","authenticated-orcid":false,"given":"Pious D.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinnan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chevis N.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua C.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh F.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan V.","family":"Chitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,21]]},"reference":[{"issue":"10","key":"896_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/cir.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56\u2013e528. https:\/\/doi.org\/10.1161\/cir.0000000000000659.","journal-title":"Circulation."},{"issue":"12","key":"896_CR2","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/hs1201.100209","volume":"32","author":"PL Kolominsky-Rabas","year":"2001","unstructured":"Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32(12):2735\u201340. https:\/\/doi.org\/10.1161\/hs1201.100209.","journal-title":"Stroke."},{"issue":"1","key":"896_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000341410","volume":"40","author":"ML Flaherty","year":"2013","unstructured":"Flaherty ML, Kissela B, Khoury JC, Alwell K, Moomaw CJ, Woo D, et al. Carotid artery stenosis as a cause of stroke. Neuroepidemiology. 2013;40(1):36\u201341. https:\/\/doi.org\/10.1159\/000341410.","journal-title":"Neuroepidemiology."},{"issue":"8","key":"896_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11936-017-0564-0","volume":"19","author":"AM Wabnitz","year":"2017","unstructured":"Wabnitz AM, Turan TN. Symptomatic carotid artery stenosis: surgery, stenting, or medical therapy? Curr Treat Options Cardiovasc Med. 2017;19(8):62. https:\/\/doi.org\/10.1007\/s11936-017-0564-0.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"896_CR5","unstructured":"Dean L. Clopidogrel therapy and CYP2C19 genotype. Medical Genetics Summaries. National Center for Biotechnology Information (US); 2018."},{"issue":"3","key":"896_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317\u201323. https:\/\/doi.org\/10.1038\/clpt.2013.105.","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"896_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2217\/pgs-2018-0072","volume":"19","author":"MD Klein","year":"2018","unstructured":"Klein MD, Lee CR, Stouffer GA. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. Pharmacogenomics. 2018;19(13):1039\u201346. https:\/\/doi.org\/10.2217\/pgs-2018-0072.","journal-title":"Pharmacogenomics."},{"issue":"1","key":"896_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1515\/jomb-2015-0009","volume":"35","author":"D Ba\u010dkovi\u0107","year":"2016","unstructured":"Ba\u010dkovi\u0107 D, Ignjatovi\u0107 S, Raki\u0107evi\u0107 L, Kusi\u0107-Ti\u0161ma J, Radojkovi\u0107 D, \u010calija B, et al. Influence of Cyp2c19*2 gene variant on therapeutic response during clopidogrel treatment in patients with carotid artery stenosis. J Med Biochem. 2016;35(1):26\u201333. https:\/\/doi.org\/10.1515\/jomb-2015-0009.","journal-title":"J Med Biochem"},{"issue":"1","key":"896_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","volume":"316","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. Jama. 2016;316(1):70\u20138. https:\/\/doi.org\/10.1001\/jama.2016.8662.","journal-title":"Jama."},{"issue":"1","key":"896_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/circulationaha.116.024913","volume":"135","author":"Y Pan","year":"2017","unstructured":"Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135(1):21\u201333. https:\/\/doi.org\/10.1161\/circulationaha.116.024913.","journal-title":"Circulation."},{"issue":"2","key":"896_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cpt.780","volume":"103","author":"A Tornio","year":"2018","unstructured":"Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, et al. Investigating real-world clopidogrel pharmacogenetics in stroke using a bioresource linked to electronic medical records. Clin Pharmacol Ther. 2018;103(2):281\u20136. https:\/\/doi.org\/10.1002\/cpt.780.","journal-title":"Clin Pharmacol Ther"},{"issue":"25","key":"896_CR12","doi-asserted-by":"publisher","first-page":"17725","DOI":"10.18632\/oncotarget.24877","volume":"9","author":"X Yi","year":"2018","unstructured":"Yi X, Lin J, Zhou J, Wang Y, Huang R, Wang C. The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke. Oncotarget. 2018;9(25):17725\u201334. https:\/\/doi.org\/10.18632\/oncotarget.24877.","journal-title":"Oncotarget"},{"issue":"4","key":"896_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jstrokecerebrovasdis.2004.06.003","volume":"13","author":"J Adamson","year":"2004","unstructured":"Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability? J Stroke Cerebrovasc Dis. 2004;13(4):171\u20137. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2004.06.003.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3","key":"896_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/clpt.2008.89","volume":"84","author":"D Roden","year":"2008","unstructured":"Roden D, Pulley J, Basford M, Bernard G, Clayton E, Balser J, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84(3):362\u20139. https:\/\/doi.org\/10.1038\/clpt.2008.89.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"896_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/pds.2312","volume":"21","author":"SE Andrade","year":"2012","unstructured":"Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):100\u201328. https:\/\/doi.org\/10.1002\/pds.2312.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"896_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/clpt.2011.371","volume":"92","author":"JM Pulley","year":"2012","unstructured":"Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92(1):87\u201395. https:\/\/doi.org\/10.1038\/clpt.2011.371.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"896_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1197\/jamia.M3378","volume":"17","author":"H Xu","year":"2010","unstructured":"Xu H, Stenner S, Doan S, Johnson K, Waitman L, Denny J. MedEx: a medication information extraction system for clinical narratives. J Am Med Inform Assoc. 2010;17(1):19\u201324.","journal-title":"J Am Med Inform Assoc"},{"issue":"8","key":"896_CR18","doi-asserted-by":"publisher","first-page":"e0135834","DOI":"10.1371\/journal.pone.0135834","volume":"10","author":"N McCormick","year":"2015","unstructured":"McCormick N, Bhole V, Lacaille D, Avina-Zubieta JA. Validity of diagnostic codes for acute stroke in administrative databases: a systematic review. PLoS One. 2015;10(8):e0135834. https:\/\/doi.org\/10.1371\/journal.pone.0135834.","journal-title":"PLoS One"},{"issue":"3","key":"896_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","volume":"379","author":"SC Johnston","year":"2018","unstructured":"Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1800410.","journal-title":"N Engl J Med"},{"key":"896_CR20","doi-asserted-by":"publisher","first-page":"25478","DOI":"10.1038\/srep25478","volume":"6","author":"W-Y Zhu","year":"2016","unstructured":"Zhu W-Y, Zhao T, Xiong X-Y, Li J, Wang L, Zhou Y, et al. Association of CYP2C19 polymorphisms with the clinical efficacy of clopidogrel therapy in patients undergoing carotid artery stenting in Asia. Sci Rep. 2016;6:25478. https:\/\/doi.org\/10.1038\/srep25478.","journal-title":"Sci Rep"},{"issue":"8","key":"896_CR21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/j.1538-7836.2008.03050.x","volume":"6","author":"K Umemura","year":"2008","unstructured":"Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008;6(8):1439\u201341. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.03050.x.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"896_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cpt.1067","volume":"105","author":"M Saiz-Rodr\u00edguez","year":"2019","unstructured":"Saiz-Rodr\u00edguez M, Romero-Palaci\u00e1n D, Villalobos-Vilda C, Caniego JL, Belmonte C, Koller D, et al. Influence of CYP2C19 phenotype on the effect of clopidogrel in patients undergoing a percutaneous neurointervention procedure. Clin Pharmacol Ther. 2019;105(3):661\u201371. https:\/\/doi.org\/10.1002\/cpt.1067.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"896_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3174\/ajnr.A4481","volume":"37","author":"M Lin","year":"2016","unstructured":"Lin M, Todaro M, Chan J, Churilov L, Zhu WS, Ramdave S, et al. Association between CYP2C19 polymorphisms and outcomes in cerebral endovascular therapy. AJNR Am J Neuroradiol. 2016;37(1):108\u201313. https:\/\/doi.org\/10.3174\/ajnr.A4481.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"16","key":"896_CR24","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1001\/jama.2010.1566","volume":"304","author":"V Fuster","year":"2010","unstructured":"Fuster V, Sweeny JM. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. Jama. 2010;304(16):1839\u201340. https:\/\/doi.org\/10.1001\/jama.2010.1566.","journal-title":"Jama."},{"issue":"2","key":"896_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","volume":"11","author":"LH Cavallari","year":"2018","unstructured":"Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(2):181\u201391. https:\/\/doi.org\/10.1016\/j.jcin.2017.07.022.","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"896_CR26","doi-asserted-by":"publisher","first-page":"e002069-e","DOI":"10.1161\/CIRCGEN.117.002069","volume":"11","author":"CR Lee","year":"2018","unstructured":"Lee CR, Sriramoju VB, Cervantes A, Howell LA, Varunok N, Madan S, et al. Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circ Genom Precis Med. 2018;11(4):e002069-e. https:\/\/doi.org\/10.1161\/CIRCGEN.117.002069.","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"896_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12967-018-1469-8","volume":"16","author":"LH Cavallari","year":"2018","unstructured":"Cavallari LH, Franchi F, Rollini F, Been L, Rivas A, Agarwal M, et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med. 2018;16(1):92. https:\/\/doi.org\/10.1186\/s12967-018-1469-8.","journal-title":"J Transl Med"}],"container-title":["Translational Stroke Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-021-00896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12975-021-00896-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-021-00896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T09:41:04Z","timestamp":1642498864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12975-021-00896-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1007\/s12975-021-00896-3","relation":{},"ISSN":["1868-4483","1868-601X"],"issn-type":[{"type":"print","value":"1868-4483"},{"type":"electronic","value":"1868-601X"}],"subject":[],"published":{"date-parts":[[2021,2,21]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study approved by Vanderbilt Institutional Review Board #190780","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Waived due to retrospective design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Waived due to retrospective design.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Dr. Rohan V. Chitale receives research grants from Medtronic and Cerenovus. Dr. Josh F. Peterson consults for Color Genomics.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}